Under way, not recruiting
Maxigesic for Postoperative Pain Control After Laparoscopic or Robotic Gastrectomy
NCT07768514 · Seoul National University Bundang Hospital · Updated 17 Aug 2026
- What is being tested
- Acetaminophen and Ibuprofen; Acetaminophen
- For
- Stomach Neoplasms
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 19 years and older. About 90 people. The full rules are on the registry page.
- Where
- South Korea
- When
- Starts or started 21 Nov 2025, ends 25 Dec 2026. Registered 17 Aug 2026.
- Results
- None posted yet.
In the researchers' words
This prospective, randomized, phase 4 clinical trial aims to evaluate the efficacy and safety of intravenous Maxigesic, a fixed-dose combination of acetaminophen and ibuprofen, for postoperative pain control in patients undergoing laparoscopic or robotic gastrectomy for gastric cancer. A total of 90 participants will be randomly assigned to receive either Maxigesic or intravenous acetaminophen. The primary objective is to compare postoperative pain control between the two groups using the sum of pain intensity differences over 72 hours (SPID72). Secondary outcomes include postoperative pain scores, opioid consumption, rescue analgesic use, antiemetic use, and safety outcomes.
Sites
- Seoul National University Bundang HospitalSeongam, Gyeonggi-do, South Korea